5-Bromo-1-methyl-3-(2-(oxetan-3-yl)-1,2,3,4-tetrahydroisoquinolin-6-ylamino)pyrazin-2(1H)-one → (2-{4,4-Dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.02,6]dodeca-1(8),2(6)-dien-10-yl}-4-fluoro-6-(4-methyl-6-{[2-(oxetan-3-yl)-1,2,3,4-tetrahydroisoquinolin-6-yl]amino}-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)methyl Acetate
Reaction equation
C(OCC1C(N2CCN3C4CCCCC=4C=C3C2=O)=CC=CC=1C1C=C(NC2C=CC(F)=CN=2)C(=O)N(C)C=1)(=O)C.[C:42]([O:45][CH2:46][C:47]1[C:52](B2OC(C)(C)C(C)(C)O2)=[CH:51][C:50]([F:62])=[CH:49][C:48]=1[N:63]1[CH2:74][CH2:73][C:72]2[C:71]3[CH2:70][C:69]([CH3:76])([CH3:75])[CH2:68][C:67]=3[S:66][C:65]=2[C:64]1=[O:77])(=[O:44])[CH3:43].Br[C:79]1[N:80]=[C:81]([NH:87][C:88]2[CH:89]=[C:90]3[C:95](=[CH:96][CH:97]=2)[CH2:94][N:93]([CH:98]2[CH2:101][O:100][CH2:99]2)[CH2:92][CH2:91]3)[C:82](=[O:86])[N:83]([CH3:85])[CH:84]=1>>[C:42]([O:45][CH2:46][C:47]1[C:52]([C:79]2[N:80]=[C:81]([NH:87][C:88]3[CH:89]=[C:90]4[C:95](=[CH:96][CH:97]=3)[CH2:94][N:93]([CH:98]3[CH2:99][O:100][CH2:101]3)[CH2:92][CH2:91]4)[C:82](=[O:86])[N:83]([CH3:85])[CH:84]=2)=[CH:51][C:50]([F:62])=[CH:49][C:48]=1[N:63]1[CH2:74][CH2:73][C:72]2[C:71]3[CH2:70][C:69]([CH3:75])([CH3:76])[CH2:68][C:67]=3[S:66][C:65]=2[C:64]1=[O:77])(=[O:44])[CH3:43]Participants
4
Reactant 3
HCID 580442615-Bromo-1-methyl-3-(2-(oxetan-3-yl)-1,2,3,4-tetrahydroisoquinolin-6-ylamino)pyrazin-2(1H)-one
HCID 67016224(2-{4,4-Dimethyl-9-oxo-7-thia-10-azatricyclo[6.4.0.02,6]dodeca-1(8),2(6)-dien-10-yl}-4-fluoro-6-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methyl Acetate
HCID 680965952-(5-(5-Fluoropyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl AcetateProduct 1
Procedure
Following the procedures as described for 148b and starting with 247b and 305 mg of 222a, 277 mg of 249a was obtained as a yellow solid (51%). MS: [M+H]+ 698.
Sources & evidence
- ORD record
- ord-d3d08dc658374c3cba14bf299485128a
- Source dataset
- uspto-grants-2013_12
- Patent number
- US08618107B2
Reaction notes
Loading…